Hot off the wire: MICROCAP DAILY BioElectron
Post# of 8464
(Total Views: 848)
Posted On: 01/05/2022 8:51:11 AM
Hot off the wire:
MICROCAP DAILY
BioElectronics Corp. (OTCPINK: BIEL) Major Reversal Brewing as Pain Management Pioneer Reports Record Revenues & Readies Launch of its KT Recovery+ WaveTM in the UK
BioElectronics Corp. (OTCPINK: BIEL) is heating up in recent trading and signaling it may be ready for a major reversal northbound off $0.001 support levels. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board. The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere as so many penny stocks did last year – a break over $0.008 and its blue skies ahead for BIEL.
BIEL sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year. BioElectronics is making big moves and quickly gaining traction in an enormous market; chronic pain affects approximately 1.5 billion people globally – more than heart disease, cancer, and diabetes. Chronic pain costs $700 billion annually in the US and Europe alone. BioElectronics product line of drug-free pain relievers meets these needs and is ready to seize this global opportunity. The Company has received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
Bioelectronics Corp. (OTCPINK: BIEL) is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative pain and wound care. In February 2017, BioElectronics received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain. More recently BIEL received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
BIEL current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use.
The Company has a partnership with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer marketplace under the DonJoy® BIEL also has an OEM agreement in place with KT Health, LLC that incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. KT Health, LLC recently received its initial order to launch its KT Recovery+ WaveTM in the United Kingdom and intends to continue expansion into other markets. Sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year.
MICROCAP DAILY
BioElectronics Corp. (OTCPINK: BIEL) Major Reversal Brewing as Pain Management Pioneer Reports Record Revenues & Readies Launch of its KT Recovery+ WaveTM in the UK
BioElectronics Corp. (OTCPINK: BIEL) is heating up in recent trading and signaling it may be ready for a major reversal northbound off $0.001 support levels. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board. The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere as so many penny stocks did last year – a break over $0.008 and its blue skies ahead for BIEL.
BIEL sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year. BioElectronics is making big moves and quickly gaining traction in an enormous market; chronic pain affects approximately 1.5 billion people globally – more than heart disease, cancer, and diabetes. Chronic pain costs $700 billion annually in the US and Europe alone. BioElectronics product line of drug-free pain relievers meets these needs and is ready to seize this global opportunity. The Company has received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
Bioelectronics Corp. (OTCPINK: BIEL) is a leader in non-invasive electroceuticals and the manufacturer of industry leading disposable, drug-free, pain therapy devices for the over-the-counter treatment of back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative pain and wound care. In February 2017, BioElectronics received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain. More recently BIEL received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA).
BIEL current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use.
The Company has a partnership with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer marketplace under the DonJoy® BIEL also has an OEM agreement in place with KT Health, LLC that incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. KT Health, LLC recently received its initial order to launch its KT Recovery+ WaveTM in the United Kingdom and intends to continue expansion into other markets. Sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year.
(2)
(0)